For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Astute Medical, Inc.

USPTO Granted Patents = 51

CIPO Patents = 3

EPO Patents = 44

Trademarks = 8

Forward Citations = 196

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Paul H McPherson (43 out of 69 patents)

Joseph Anderberg (38 out of 42 patents)

Jeff Gray (36 out of 52 patents)

4. Kevin Nakamura (36 out of 36 patents)

5. James Patrick Kampf (28 out of 37 patents)

6. Thomas Kwan (6 out of 15 patents)

7. Ravi A Vijayendran (6 out of 6 patents)

8. Srivatsa Venkatasubbarao (5 out of 6 patents)

9. John Alston Kellum (4 out of 26 patents)

10. Donald Chalfin (2 out of 2 patents)

11. John Van Bosch (2 out of 5 patents)

12. Lakhmir S Chawla (1 out of 21 patents)

13. Alexander Zarbock (1 out of 1 patent)

14. Hua Wang (1 out of 2 patents)

15. Kai Singbartl (8 patents)

Core Competencies:

Renal Injury

Renal Failure

C-C Motif Chemokine Ligand 14

Insulin-Like Growth Factor-Binding Protein 7

Tissue Inhibitor of Metalloproteinase 2

Follistatin-Related Protein 3

Acute Kidney Injury

Biological Assays

Prognosis Methods

Diagnosis Compositions

Lateral Flow Assay

Stroke Diagnosis

51 patents: Sort by Forward Citations

1. 12203944 - Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement (2025-01-21),

2. 12203941 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2025-01-21),

3. 12123882 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-10-22),

4. 12099067 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-09-24),

5. 12019080 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2024-06-25),

6. 11891439 - Antibodies and assays for CCL14 (2024-02-06),

7. 11761967 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2023-09-19),

8. 11754566 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2023-09-12),

9. 11718682 - Assays for TIMP2 having improved performance in biological samples (2023-08-08),

10. 11506672 - Follistatin-related protein 3 for diagnosis and prognosis of renal injury and renal failure (2022-11-22),

11. 11454635 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-09-27),

12. 11353465 - Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement (2022-06-07),

13. 11346846 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-05-31),

14. 11333671 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-05-17),

15. 11262363 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure (2022-03-01),

Astute Medical is a company focused on improving patient outcomes through the identification and validation of novel biomarkers for acute medical conditions. They develop and commercialize diagnostic tests to aid in the early detection and prognosis of acute kidney injury and sepsis.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

51 Patents

#118 in San Diego, CA

#1,580 in California

#6,661 in US

#13,382 in the World

San Diego, CA, United States of America

Astute Medical, Inc.

Forward Citations = 196

14 inventors:

Paul H McPherson (43 out of 69 patents)

Joseph Anderberg (38 out of 42 patents)

Jeff Gray (36 out of 52 patents)

4. Kevin Nakamura (36 out of 36 patents)

5. James Patrick Kampf (28 out of 37 patents)

Please report any incorrect information to support@idiyas.com

Loading…